Robin van Eenige
The prevalence of obesity has reached epidemic proportions. Disturbingly, obesity has been associated with various diseases, including type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVDs), with CVDs being considered the primary cause of death worldwide. Currently available cholesterol-lowering medication only prevents approx. one third of CVD events. The residual risk can at least in part be explained by high circulating triglycerides within triglyceride-rich lipoprotein remnants. Therefore, I am interested in finding novel therapeutic strategies that improve lipid metabolism. In recent years, I have contributed to research that improve lipid metabolism amongst others by stimulating thermogenesis within (brown) adipose tissue and/or that investigate underlying mechanisms (e.g. EBioMedicine 2023, Atherosclerosis 2023, Pharmacol Res 2023, Mol Metab 2022, Circulation 2022, J Lipid Res 2021). I also contribute to studies aimed at investigating the (beneficial) effects of lifestyle interventions on CVD risk in humans, for example the coolBAT study (coolBAT.nl).